Empagliflozin Attenuates Renal and Urinary Markers of Tubular Epithelial Cell Injury in Streptozotocin-induced Diabetic Rats

被引：18

作者：

Ashrafi Jigheh, Zahra ^{[1
,2
]}

Ghorbani Haghjo, Amir ^{[3
]}

Argani, Hassan ^{[4
]}

Roshangar, Leila ^{[5
]}

Rashtchizadeh, Nadereh ^{[3
]}

Sanajou, Davoud ^{[1
]}

Nazari Soltan Ahmad, Saeed ^{[1
]}

Rashedi, Jalil ^{[1
]}

Dastmalchi, Siavoush ^{[3
]}

Mesgari Abbasi, Mehran ^{[6
]}

机构：

[1] Tabriz Univ Med Sci, Fac Med, Dept Biochem, Tabriz, Iran

[2] Tabriz Univ Med Sci, Student Res Ctr, Tabriz, Iran

[3] Tabriz Univ Med Sci, Biotechnol Res Ctr, Goshgasht Ave,POB 14711, Tabriz 5166614711, Iran

[4] Beheshti Univ Med Sci, Urol & Nephrol Res Ctr, Tehran, Iran

[5] Tabriz Univ Med Sci, Stem Cell Res Ctr, Tabriz, Iran

[6] Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz, Iran

来源：

INDIAN JOURNAL OF CLINICAL BIOCHEMISTRY | 2020年 / 35卷 / 01期

关键词：

Diabetic nephropathy; Empagliflozin; Tubular injury markers; PROGRESSION; BIOMARKERS; NEPHROPATHY; INHIBITION;

D O I：

10.1007/s12291-018-0790-6

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Empagliflozin, a SGLT-2 inhibitor, improves diabetic nephropathy through its pleiotropic anti-inflammatory effects. The present study aims to evaluate empagliflozin effects on renal and urinary levels of tubular epithelial cell injury markers in streptozotocin-induced diabetic rats. Empagliflozin at 10 mg/kg (p.o.) was administered for 4 weeks, beginning 8 weeks after induction of diabetes. Renal function as well as markers of renal tubular epithelial cell injury were assessed in kidney tissue homogenates and urine. Empagliflozin was able to ameliorate diabetes induced elevations in serum cystatin C levels. It also alleviated renal KIM-1/NGAL levels and urinary albumin, alpha-GST, and RBP excretions. In addition to decreasing urinary levels of cell cycle arrest indices i.e. TIMP-2 and IGFBP7, empagliflozin mitigated acetylated NF-kappa B levels in renal tissues of diabetic rats. As a whole, these findings reveal empagliflozin capability in improving diabetic nephropathy via ameliorating indices of renal inflammation, injury, and cell cycle arrest on streptozotocin-induced diabetic rats.

引用

页码：109 / 114

页数：6

共 28 条

[1]

Chen SJ, 2015, INT J CLIN EXP MED, V8, P18225

[2] Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes [J].

Duckworth, William ;

Abraira, Carlos ;

Moritz, Thomas ;

Reda, Domenic ;

Emanuele, Nicholas ;

Reaven, Peter D. ;

Zieve, Franklin J. ;

Marks, Jennifer ;

Davis, Stephen N. ;

Hayward, Rodney ;

Warren, Stuart R. ;

Goldman, Steven ;

McCarren, Madeline ;

Vitek, Mary Ellen ;

Henderson, William G. ;

Huang, Grant D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (02) :129-U62

[3] Mechanisms of maladaptive repair after AKI leading to accelerated kidney ageing and CKD [J].

Ferenbach, David A. ;

Bonventre, Joseph V. .

NATURE REVIEWS NEPHROLOGY, 2015, 11 (05) :264-276

[4] SGLT2 Inhibitors and the Diabetic Kidney [J].

Fioretto, Paola ;

Zambon, Alberto ;

Rossato, Marco ;

Busetto, Luca ;

Vettor, Roberto .

DIABETES CARE, 2016, 39 :S165-S171

[5] Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrumof heart failure risk in the EMPA-REG OUTCOME® trial [J].

Fitchett, David ;

Butler, Javed ;

van de Borne, Philippe ;

Zinman, Bernard ;

Lachin, John M. ;

Wanner, Christoph ;

Woerle, Hans J. ;

Hantel, Stefan ;

George, Jyothis T. ;

Johansen, Odd Erik ;

Inzucchi, Silvio E. ;

Aizenberg, D. ;

Ulla, M. ;

Waitman, J. ;

De Loredo, L. ;

Farias, J. ;

Fideleff, H. ;

Lagrutta, M. ;

Maldonado, N. ;

Colombo, H. ;

Ferre Pacora, F. ;

Wasserman, A. ;

Maffei, L. ;

Lehman, R. ;

Selvanayagam, J. ;

d'Emden, M. ;

Fasching, P. ;

Paulweber, B. ;

Toplak, H. ;

Luger, A. ;

Drexel, H. ;

Prager, R. ;

Schnack, C. ;

Schernthaner, G. ;

Fliesser-Goerzer, E. ;

Kaser, S. ;

Scheen, A. ;

Van Gaal, L. ;

Hollanders, G. ;

Kockaerts, Y. ;

Capiau, L. ;

Chachati, A. ;

Persu, A. ;

Hermans, M. ;

Vantroyen, D. ;

Vercammen, C. ;

Van de Borne, P. ;

Mathieu, C. ;

Benhalima, K. ;

Lienart, F. .

EUROPEAN HEART JOURNAL, 2018, 39 (05) :363-370

[6] MECHANISMS OF DIABETIC COMPLICATIONS [J].

Forbes, Josephine M. ;

Cooper, Mark E. .

PHYSIOLOGICAL REVIEWS, 2013, 93 (01) :137-188

[7] Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy [J].

Fried, Linda F. ;

Emanuele, Nicholas ;

Zhang, Jane H. ;

Brophy, Mary ;

Conner, Todd A. ;

Duckworth, William ;

Leehey, David J. ;

McCullough, Peter A. ;

O'Connor, Theresa ;

Palevsky, Paul M. ;

Reilly, Robert F. ;

Seliger, Stephen L. ;

Warren, Stuart R. ;

Watnick, Suzanne ;

Peduzzi, Peter ;

Guarino, Peter .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (20) :1892-1903

[8] Effect of a multifactorial intervention on mortality in type 2 diabetes [J].

Gaede, Peter ;

Lund-Andersen, Henrik ;

Parving, Hans-Henrik ;

Pedersen, Oluf .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (06) :580-591

[9] Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice [J].

Gallo, Linda A. ;

Ward, Micheal S. ;

Fotheringham, Amelia K. ;

Zhuang, Aowen ;

Borg, Danielle J. ;

Flemming, Nicole B. ;

Harvie, Ben M. ;

Kinneally, Toni L. ;

Yeh, Shang-Ming ;

McCarthy, Domenica A. ;

Koepsell, Hermann ;

Vallon, Volker ;

Pollock, Carol ;

Panchapakesan, Usha ;

Forbes, Josephine M. .

SCIENTIFIC REPORTS, 2016, 6

[10] The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension [J].

Gembardt, Florian ;

Bartaun, Christoph ;

Jarzebska, Natalia ;

Mayoux, Eric ;

Todorov, Vladimir T. ;

Hohenstein, Bernd ;

Hugo, Christian .

AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2014, 307 (03) :F317-F325

← 1 2 3 →